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http:WHAT THIS PAPER ADDS
Because the pathophysiology of peri-operative stroke is multifactorial, no single monitoring or therapeutic
strategy will signiﬁcantly reduce its prevalence. This large prospective series of themed audit/research projects
identiﬁed three strategies for preventing stroke after carotid endarterectomy, which are readily transferable into
surgical practices elsewhere.The objective of this review was to identify causes of stroke/death after carotid endarterectomy (CEA) and to
develop transferable strategies for preventing stroke/death after CEA, via an overview of a 21-year series of
themed research and audit projects. Three preventive strategies were identiﬁed: (i) intra-operative transcranial
Doppler (TCD) ultrasound and completion angioscopy which virtually abolished intra-operative stroke, primarily
through the removal of residual luminal thrombus prior to restoration of ﬂow; (ii) dual antiplatelet therapy with a
single 75-mg dose of clopidogrel the night before surgery in addition to regular 75 mg aspirin which virtually
abolished post-operative thromboembolic stroke and may also have contributed towards a decline in stroke/
death following major cardiac events; and (iii) the provision of written guidance for managing post-CEA
hypertension which was associated with virtual abolition of intracranial haemorrhage and stroke as a result of
hyperperfusion syndrome. The pathophysiology of peri-operative stroke is multifactorial and no single monitoring
or therapeutic strategy will reduce its prevalence. Two of the preventive strategies developed during this 21-year
project (peri-operative dual antiplatelet therapy, published guidance for managing post-CEA hypertension) are
easily transferable to practices elsewhere.
 2013 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.
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“We are too much accustomed to attribute to a single
cause, that which is the product of several, and the
majority of our controversies come from that”
Baron Justus von Leibig (1803e1873)
One of the paradoxes with carotid endarterectomy (CEA) is
that although proven to prevent stroke in the long term, it is
associated with a small risk of procedural stroke that di-
minishes the overall beneﬁt conferred to the patient. For
example; surgeons performing CEA in symptomatic patients
with a 7.5% risk (as in ECST1)will prevent 85 strokes/1000CEAs
at 5 years (45% relative risk reduction (RRR) compared with
medical therapy). However, if the operative risk were reduced
to 2%, 142 strokes would be prevented at 5 years (74% RRR).rresponding author. A.R. Naylor, Vascular Surgery Group, Division of
ascular Sciences, Clinical Sciences Building, Leicester Royal In-
, Leicester LE2 7LX, United Kingdom.
il address: ross.naylor@uhl-tr.nhs.uk (A.R. Naylor).
-5884/$ e see front matter  2013 European Society for Vascular
. Published by Elsevier Ltd. All rights reserved.
//dx.doi.org/10.1016/j.ejvs.2013.05.005Surgeons have long been aware of this paradox and
strategies have been proposed for minimising procedural
risks, but few have inﬂuenced practice, other than perhaps
patch angioplasty.2 Most have, otherwise, met with scep-
ticism, leaving surgeons to largely practice what they were
taught during their training. Upon reﬂection, a key factor in
why this has happened is that most studies have tended to
evaluate a single therapeutic or monitoring strategy (usually
retrospectively and usually in isolation), only to condemn it
to obscurity when the overall risk of stroke fails to decline.
Given the multiple causes of peri-operative stroke, this was
always going to be a naïve approach to prevention.
Over the last 21 years, a series of themed research/audit
projects have been undertaken as part of a systematic
approach to understanding the causes of procedural stroke.
This was then followed by the development of generalisable
and transferable strategies for their prevention. Each
started with a speciﬁc goal (e.g. the prevention of intra-
operative stroke), which was then addressed through pro-
spective research studies and complementary audits before
moving on to the next question (e.g. the prevention of post-
CEA thrombotic stroke). Although many of the individual
projects have been published previously, this is the ﬁrst
Figure 1. The transcranial Doppler probe has been focussed onto
the right middle cerebral artery and secured into position using an
elasticated headband. It is protected from dislodgement by a semi-
circular metal headguard that does not interfere with access to the
operative ﬁeld.
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that enables the reader to see how each strategy interacted
towards achieving the goal of preventing peri-operative
stroke.
BACKGROUND TO THE PROJECT
During the 21-year period between January 1, 1992 and
December 31, 2012, 2300 patients underwent carotid
endarterectomy in the Vascular Unit at Leicester Royal In-
ﬁrmary. Throughout this time, a series of research and/or
prospective audits were undertaken as part of a systematic
approach to preventing stroke and/or death in the peri-
operative period. Any studies involving randomised trials
(e.g. dual antiplatelet therapy3) or the prospective evalua-
tion of new preventive strategies4 were carried out only
after Ethical Committee approval and patient consent.
These research projects were then interspersed with
sequential audits the role of which was to determine
whether changes in practice inﬂuenced outcome. The Lei-
cestershire, Northamptonshire and Rutland Research Ethics
Committee were consulted throughout and advised that
the audits did not fall under the remit of the NHS Research
Ethics Committee as they represented audit/service
evaluation.
Changing patient demographics
In common with most UK units, the vast majority of patients
undergoing CEA in this series had reported symptoms
within the preceding 6 months. Relatively few asymptom-
atic patients underwent CEA in the Leicester Unit prior to
1995. Between October 1, 1995 and December 31, 2012,
1933 patients underwent carotid revascularisation, but only
271 (14%) were neurologically asymptomatic. What has
changed, however, during the 21-year period of study was
the move towards expedited intervention in symptomatic
patients. In the latter four-year period between October 1,
2008 and December 31, 2012, 452 symptomatic patients
underwent CEA with 71% undergoing their surgery within
14 days (46% within seven days) of their most recent
symptom.
Pre-operative assessment
Admission and referral practices changed during the 21-year
period. Between 1992 and 2008, patients were seen in the
Vascular Surgery Outpatient Clinic and listed for CEA. During
this time, the unit adhered to National Guidelines that
recommended that CEA be carried out in symptomatic pa-
tients within 6 months of the index event. Only a relative
minority underwent expedited/emergency CEA. Secondary
preventive strategies (antiplatelet, statin, antihypertensive
therapy) were usually left to the family doctor to supervise.
Patients were prescribed aspirin prior to surgery (75e
150 mg) and this was not discontinued during the peri-
operative period. Peri-operative statin usage increased
with time, especially after publication of the British Heart
Protection Study in 2002.5 However, although efforts were
made to optimise hypertension therapy prior to CEA, thiswas not as rigorously enforced compared with the latter
years (2008e2012).
After 2006, there was a more concerted drive towards
intervening more quickly following the index event6 in
symptomatic patients and in October 2008, a rapid access,
single-visit TIA clinic (operating daily all year) was estab-
lished and run by consultant stroke physicians.7 The physi-
cians now assumed responsibility for correcting risk factors
and for starting ‘best medical therapy’ in the clinic. In
addition, any symptomatic patient found to have an ipsi-
lateral 50e99% stenosis was transferred directly from the
TIA clinic to the Vascular Unit for expedited CEA. Pre-
operative mono-antiplatelet therapy changed to dual anti-
platelet therapy (see Prevention of post-operative throm-
boembolic stroke) and there was greater emphasis placed
on ensuring that all patients received statin therapy
throughout the peri-operative period and that uncon-
trolled/poorly controlled hypertension was corrected prior
to surgery.
Operative technique
The operative procedure has remained essentially un-
changed since 1992; general anaesthesia, a policy favouring
routine patching (see below), routine shunting (Pruitt-Ina-
hara), systemic heparinisation (5000u intravenous unfrac-
tionated heparin) apart from during a randomised trial
comparing low molecular weight versus unfractionated
heparin8 and distal intimal tacking sutures. Out of the 2300
patients; 68 received a carotid vein bypass because of
excessive vessel wall thinning or tortuosity, and 2232 un-
derwent patch closure of the arteriotomy (saphenous vein
in 201, prosthetic in 2031).
Throughout the 21-year period, patients with an acces-
sible temporal window underwent intra-operative trans-
cranial Doppler (TCD) monitoring of blood ﬂow in the
ipsilateral middle cerebral artery (MCA) using a ﬁxed 2-MHz
head probe, protected by a semi-circular headguard (Fig. 1).
The surgeon and anaesthetist aimed to ensure that mean
blood ﬂow velocity in the middle cerebral artery (MCAV)
A.R. Naylor et al. 163was >15 cm/s. A threshold of 15 cm/s was chosen because
Halsey had previously shown this to correlate with loss of
cerebral electrical activity.9 If the MCAV was <15 cm/s after
shunt insertion, the shunt was repositioned to exclude
abutment against the distal ICA lumen. If MCAV remained
<15 cm/s, blood pressure was therapeutically elevated by
the anaesthetist.
In the pilot project (1992e1993), 100 patients underwent
completion angioscopy wherever possible10 and this policy
was then continued throughout the next 21 years. A 5-mm
space was retained adjacent to the origin of the ECA
following near completion of the patch closure. The shunt
was removed and all vessels back vented and irrigated with
heparinised saline. The lumen of the endarterectomy zone
was then inspected with a ﬂexible hysteroscope (Olympus
1070-48). Our policy was to repair all intimal ﬂaps >3 mm
and aspirate any luminal thrombus from the operative ﬁeld
(Fig. 2).Post-operative monitoring
During the 15-year period (October 1995eJuly 2009), pa-
tients with an accessible temporal window underwent
routine post-operative TCD monitoring in order to identify
patients at risk of progressing to a stroke as a result of
post-operative carotid thrombosis (POCT). Between
October 1995 and December 1997, patients underwent sixFigure 2. Completion angioscopy. (A) Normal distal endarterec-
tomy zone; (B) large distal ICA intimal ﬂap; (C) large thrombus
adherent to proximal endarterectomy zone adjacent to common
carotid intimal step; (D) large tongue of thrombus that formed
around the shunt in the distal ICA which then ‘fell’ into the end-
arterectomy zone during back-bleeding and which was then held
by the distal ICA clamp. Note. Figure 2A, B and D were reproduced
with permission from Sharpe et al.18 Copyright 2012 by Elsevier.
Figure 2C was reproduced with permission from Naylor et al.19
Copyright 2000 by Elsevier.hours of post-operative TCD monitoring.11 Monitoring was
reduced to three hours following a 1997 audit of prac-
tice,12 and this practice was continued until July 2006
when a second audit suggested that monitoring was
required for only 30 minutes.13 Routine post-operative TCD
monitoring ceased in August 200914 for reasons that will
be detailed later.
Peri-operative morbidity and mortality
Patients who recovered from anaesthesia with a new
neurological deﬁcit (which persisted for >24 hours) were
deﬁned as having suffered an intra-operative stroke. Pa-
tients who recovered from anaesthesia with no new
neurological deﬁcit, but who then suffered a neurological
deﬁcit lasting >24 hours within 30 days of surgery were
deﬁned as having suffered a post-operative stroke.
Since 1992, unit policy has been to immediately re-
explore the endarterectomy zone in any patient recov-
ering from anaesthesia with a new neurological deﬁcit or a
deﬁcit developing in the ﬁrst 12 post-operative hours. CT
imaging is not usually undertaken in this situation before
surgery, as it is assumed that the stroke was thromboem-
bolic and the primary aim would be to remove any luminal
thrombus and restore ﬂow as soon as possible. CT imaging
is, however, performed in patients presenting with a new
neurological deﬁcit after 12 hours has elapsed on the basis
that intracranial haemorrhage (ICH) or stroke resulting from
hyperperfusion syndrome might be present.
Any patient suffering a new neurological deﬁcit within 30
days of surgery was assessed (wherever possible) by a
neurologist/stroke physician. All underwent autopsy and/or
a battery of investigations designed to identify the most
likely underlying cause: (i) CT scan (to exclude intracranial
haemorrhage), diagnose recent infarction [cortical, embolic,
sub-cortical, watershed] and identify patterns of white
matter oedema associated with the hyperperfusion syn-
drome);15 (ii) colour Duplex ultrasound (to exclude ﬁlling
defects in the operated ICA, ﬂow abnormalities suggestive
of inﬂow or outﬂow problems); (iii) more recently CT
angiography to rapidly evaluate vascular anatomy from arch
to circle of Willis); and (iv) TCD to diagnose ongoing em-
bolisation, high MCAV (suggesting hyperperfusion syn-
drome), inter-hemispheric MCAV asymmetry suggesting
multiple MCA branch occlusions, absent MCA mainstem
signal suggesting embolic occlusion of MCA and MCAV
similar to that during carotid clamping suggesting carotid
thrombosis. The classiﬁcation ‘unknown’ was applied only if
all of these investigations were normal.
Discharge
Patients were usually discharged on day 2 on regular aspirin
(75 mg daily), statin and antihypertensive therapy. No
further clopidogrel was administered unless this was
mandated for other reasons (e.g. cardiac). All patients were
reviewed in the outpatient department four to six weeks
after surgery, and then discharged from regular review
unless they were part of an ongoing trial.
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Table 1 details how the aetiology of peri-operative stroke
(intra/post-operative) changed during the 21-year period of
study as the various preventive strategies were imple-
mented and audited. At the foot of the table, a graph shows
how the overall 30-day death/stroke rate declined over the
period of study, but not why. That is detailed below.Prevention of intra-operative stroke (1992e1995)
In a series of CEA patients undergoing pre-operative CT
imaging and a radionuclide evaluation of cerebral vascular
reserve (CVR), it had been observed that the prevalence of
intra-operative stroke was signiﬁcantly higher in patients
who entered surgery with a pre-existing neurological deﬁcit
in association with impaired CVR and CT scan evidence of
infarction.16 It was suggested that these patients might be
more vulnerable to intra-operative embolic phenomena or
low cerebral perfusion compared with others (i.e. they were
more vulnerable to the consequences of inadvertent tech-
nical error).Table 1. The inﬂuence of stroke prevention strategies on the aetiolog
(1992-2012).The pilot study (1992e1993) tested the hypothesis that
TCD monitoring and quality control (QC) might prevent
intra-operative stroke through the detection and correc-
tion of inadvertent technical error prior to restoration
of ﬂow.10 At the time, and in common with experience
elsewhere, intra-operative stroke was the commonest
type of procedural stroke affecting up to 4% of our CEA
patients.
Gaunt observed that (for us) intra-operative TCD
and completion angioscopy offered the greatest yield
for identifying technical error secondary to retained
intraluminal thrombus (Fig. 2C and D) and large intimal
ﬂaps (Fig. 2B). These defects were repaired prior to
restoration of ﬂow and in a pilot study involving 100 pa-
tients, the intra-operative stroke rate fell from 4% to 1%.10
This was then followed by a conﬁrmatory audit involving
252 consecutive CEAs between 1995 and 1996, where
completion angioscopy and intra-operative TCD was asso-
ciated with a 0% rate of intra-operative stroke.17 These
data suggested to us that that the beneﬁt afforded by QC
was real and sustained.y of intra- and post-operative stroke after carotid endarterectomy
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involved four consecutive blocks of 400 patients who
had undergone CEA between 1995 and 2010. Here the
combination of TCD and angioscopy was associated with a
0.3% prevalence of intra-operative stroke.18 In the 1600
patients under study, 7% had thrombus removed prior to
restoration of ﬂow, and 2% had large intimal ﬂaps repaired.
The consistent messages from each of the three audits
were: (i) most intra-operative strokes probably followed
embolisation of retained luminal thrombus derived from
bleeding from transected vasa vasorum onto the endar-
terectomised surface,19 or (less commonly) a dislocated
peri-shunt thrombus as in Fig. 2D). Both could occur despite
copious irrigation and venting; and (ii) even a highly expe-
rienced surgeon could still be responsible for inadvertent
technical error.18 It was salutary to note that even after 21
years of experience with angioscopy, retained luminal
thrombi were still being aspirated in 5% of patients prior to
ﬂow restoration, but the overall beneﬁt of the QC pro-
gramme was reﬂected in the 0.3% rate of intra-operative
stroke (7/2300 CEAs; Table 1).
The potential beneﬁts offered by TCD, however, have
never found widespread support,20 largely because de-
tractors expect it to fulﬁl an all encompassing preventive
role. In practice, TCD has only four intra-operative roles: (i)
diagnosing embolisation during carotid mobilisation, which
warns the surgeon of an unstable plaque and the need for
even more delicate dissection. This is especially important in
the current era of intervening in the hyperacute period afterFigure 3. TCD diagnosis of on-table carotid thrombosis which was
(MCAV ¼ 48 cm/s). (B) The ICA is clamped (MCAV ¼ 24 cm/s). (C) S
terectomy (MCAV ¼ 68 cm/s). (E) First emboli detected in ipsilateral
43 cm/s. (G) MCAV has now fallen to 27 cm/s, that is similar to when
nearly occluded. (H) The wound has been reopened and gentle hand
ipsilateral MCA, causing MCAV to increase to 40 cm/s. After re-opening
with fresh thrombus. Following removal of the thrombus, there was no
permission from Gaunt et al.22 Copyright 1994 by Elsevier.onset of symptoms; (ii) ensuring that the shunt is working
(3% do not21); (iii) ensuring that mean MCAV is >15 cm/s
during shunting, which will minimise the risk of haemody-
namic stroke9 and; (iv) to identify the very rare patient who
is actively thrombosing their endarterectomy zone during
neck closure.22 On-table carotid thrombosis can be diag-
nosed by detecting increasing rates of embolisation in the
ipsilateral MCA as the thrombus accumulates within the
endarterectomy zone and then embolises distally,4,22,23 in
association with a progressive decline in MCAV to levels
observed during carotid clamping (Fig. 3).Prevention of post-operative thromboembolic stroke
(1995e2011)
Between 1992 and 1994; the combination of TCD and
angioscopy was associated with virtual abolition of intra-
operative stroke (Table 1). However, it had no effect on
preventing stroke as a result of post-operative carotid
thrombosis (POCT), a condition previously thought to
follow uncorrected technical error. However, six of the
seven cases of stroke as a result of POCT that were re-
explored in the early post-operative period between
1992 and 1995 had no evidence of underlying technical
error, suggesting that the intra-operative QC programme
was functioning effectively. The seventh patient suffered a
fatal thrombosis 12 hours after CEA secondary to acute
false aneurysm formation because of excessive thinning of
the endarterectomy zone.diagnosed during wound closure. (A) Beginning of operation
hunt opened (MCAV ¼ 42 cm/s). (D) Flow restored after endar-
MCA (arrows). (F) After further embolisation, MCAV declines to
the ICA was clamped indicating that the ICA is either occluded or
ling of the ICA triggers the release of numerous emboli into the
the ICA, the endarterectomy zone was almost completely occluded
evidence of any underlying technical error. Note. Reproduced with
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technical error at re-exploration in late 1994 (Table 1), it
was decided that from January 1995 all patients would
receive intravenous dextran-40 therapy following restora-
tion of ﬂow. This decision was based on dextran’s perceived
rheological and antiplatelet properties, although subse-
quent research has shown that most of its antithrombotic
effects were probably mediated via enhanced in vivo ﬁbri-
nolysis, rather than any favourable rheological or anti-
platelet properties.24 For the ﬁrst 9 months of 1995, routine
dextran therapy was associated with no cases of POCT.
However, the administration of dextran to a diabetic patient
with pre-existing renal impairment was probably respon-
sible for his death as a result of multi-organ failure (1995,
Table 1). Routine dextran therapy was suspended in
September 1995, but within three weeks, another patient
suffered a stroke as a result of POCT (1995, Table 1).
Earlier work by Gaunt had shown that patients destined
to suffer a stroke as a result of POCT had increasing rates of
embolisation that could be detected using TCD (Fig. 3) and
that this phenomenon preceded onset of neurological
symptoms, sometime by up to an hour.4,22,23 The associa-
tion between high-rate embolisation and a 50% risk of
progressing on to a stroke because of POCT has now been
corroborated by multiple centres around the world22,23,25e
29 and led to a realisation that it might be possible to
identify high-risk patients by detection of increasing rates of
embolisation.
Having observed the apparent beneﬁts conferred by
dextran in terms of preventing POCT, the monitoring policy
was amended on October 1, 1995. All patients then under-
went six hours of post-operative TCD monitoring, and
intravenous dextran was only administered to patients with
high-rate embolisation, which was deﬁned as >25 emboli in
any 10-minute period.11 In practice, fewer than 5% of pa-
tients exhibited such high rates of embolisation in the early
post-operative period and went on to require dextran.11,19
On each occasion, however, embolisation rapidly dimin-
ished following dextran administration, although the dose
had to be increased in up to a third of patients.11,19 As can be
seen (Table 1), the administration of dextran to patients with
high-rate embolisation was associated with complete aboli-
tion of stroke as a result of POCT between 1995 and 2009. In
addition, POCT was never observed in any patient with zero
or low rate embolisation and who did not receive dextran.
Despite dextran’s success at preventing POCT, the
manufacturer served notice in 2006 that production was to
cease and this precipitated a strategic rethink regarding
how POCT might be prevented in the future. Somewhat
serendipitously, a series of research projects had already
identiﬁed a second approach to POCT prevention, but had
not been validated or taken further. Gaunt had previously
shown that high-rate embolisation preceded onset of
POCT,22,23 and Hayes subsequently observed that the
platelets of patients with higher rate embolisation were
more sensitive to adenosine diphosphate (ADP).30 In a
subsequent randomised trial, Payne demonstrated that
patients taking regular aspirin who received 75 mgclopidogrel (an ADP inhibitor) the night before surgery had
a highly signiﬁcant reduction in the magnitude of emboli-
sation in the early post-operative period.3
On August 1, 2006, and in anticipation of dextran’s
withdrawal but with two years stock remaining, a further
modiﬁcation to the monitoring protocol was made. Patients
were now prescribed a single 75-mg dose of clopidogrel the
night before surgery in addition to 75 mg aspirin daily. Post-
operative TCD monitoring continued and we retained the
ability to administer dextran to anyone who developed
high-rate embolisation while supplies lasted. However,
three years later, a 2009 audit observed that peri-operative
dual antiplatelet therapy had virtually abolished post-
operative embolisation and only 1/270 patients (0.4%)
required dextran;14 that is, it was now neither clinically nor
cost-effective to continue post-op TCD monitoring.
Routine post-operative TCD monitoring was abandoned
in August 2009 as pre-operative dual antiplatelet therapy
had rendered the need for selective dextran therapy
obsolete. Dual antiplatelet therapy has now been routinely
employed for almost seven years (799 CEAs; Table 1).
During this time, no patient has suffered a stroke because
of POCT. This would suggest that the administration of
75 mg clopidogrel the night before surgery, in addition to
regular aspirin, is a very simple, effective and easily trans-
ferable means of preventing post-operative thromboem-
bolic stroke.Prevention of intracranial haemorrhage and stroke as a
result of hyperperfusion syndrome (2008e2012)
Between 1995 and 2005, intra-operative stroke and stroke
as a result of POCT had effectively been abolished, but
three pathologies remained an ongoing source of morbidity
and mortality: intracranial haemorrhage (ICH), hyper-
perfusion stroke (HS) and death/stroke following acute
cardiac events (Table 1).
By 2006, there was a general consensus that post-
endarterectomy hypertension (PEH) almost always pre-
ceded ICH/HS. Unfortunately, these unpredictable surges in
blood pressure often occurred at night when the least
experienced staff were on-site and there were no guide-
lines for managing this condition. The problem was com-
pounded by colleagues in acute medicine who did not
really regard PEH as a priority and who were generally
reluctant to introduce aggressive antihypertensive therapy
in patients who had suffered recent cerebrovascular
symptoms prior to their CEA. As a consequence, there was
a haphazard approach to treating severe PEH. In late 2007
(Table 1), a patient suffered an ICH at 4:00 a.m. (18 hours
after CEA), which followed a sustained period of hyper-
tension that had not been adequately treated. This event
became the catalyst for a core group of vascular surgeons,
stroke physicians, anaesthetists and hypertension special-
ists to develop guidelines for managing post-CEA
hypertension.
These guidelines are summarised in Tables 2 and 3.
Table 2 details the ﬁrst, second and third line agents that
Table 3. Management of the patient becomes who hypertensive
on the ward (systolic BP >170 mmHg) but with NO headache,
seizure or focal neurological deﬁcit.
Patient is NOT normally taking antihypertensive therapy
First line Nifedipine Retard (10 mg), repeated after 1 h if
no change in BP. DO NOT use crushed Nifedipine capsules
Second line Bisoprolol 5.0 mg. If contra-indicated, move
to third line agent
Third line Ramipril 5 mg, repeated at 3 h if necessary
Patient IS normally on antihypertensive therapy
First line Check the patient has received normal
antihypertensive medication. If not, administer these.
Second line A [ ACE inhibitor, B [ B-Blocker,
C [ Calcium Channel Blocker, D [ Diuretic
If patient is on A, add in C (nifedipine LA 10 mg)
If patient is on C, add in A (ramipril 5 mg)
If patient is on D, add in A (ramipril 5 mg)
If patient is on Aþ C, add in D (bendroﬂuazide 2.5mg)
If patient is on A þ D, add in C (nifedipine LA 10 mg)
If patient is on A þ C þ D, add in B (bisoprolol 5 mg)
Note. Reproduced with permission from Naylor AR. Optimal
Medical Therapy during Carotid Endarterectomy: A Personal
View. Acta Chir Belg, 2009:109;285e291.
Table 2. Guidance for the management of (i) severe hypertension
in the recovery area of theatre (>170 mmHg) or (ii) back on ward
(>160 mmHg) in association with severe headache and/or
seizures.
First line: Labetalol
100 mg labetalol in 20 mL of 0.9% Saline.
(i.e. 5 mg/mL)
Give 10 mg (2 mL) boluses slowly every two min
up to 100 mg (i.e. 20 mL given over 20 min)
If BP remains elevated after 20 min, move to
second line agent
If BP reduces and does not rebound, continue
regular BP observations
If BP reduces but increases again, start infusion at
50e100 mg/h, titrating dose to BP
Second line: Hydralazine
10 mg hydralazine in 10 mL of 0.9% sodium
chloride (i.e. 1 mg/mL)
Give 2 mg (2 mL) boluses slowly every 5 min up to
10 mg (i.e. 10 mL given over 25 min)
If BP remains elevated after 25 min, move to third
line agent
If BP reduces and does not rebound, continue
regular BP observations
If BP reduces but increases again, move to third
line agent
Third line: GTN
50 mg GTN in 50 mL 0.9% sodium chloride
(i.e. 1 mg/mL)
Start infusion at 5 mL/h (5 mg/h), increasing rate
to 12 mL/h (12 mg/h), titrated to BP
Note. Reproduced with permission from Naylor AR. Optimal
Medical Therapy during Carotid Endarterectomy: A Personal
View. Acta Chir Belg, 2009:109;285e291.
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of theatre, using a threshold for intervention of systolic BP
>170 mmHg, and hypertension on the vascular ward when
there was a systolic BP >160 mmHg in the presence of
headache, seizure or neurological deﬁcit. Table 3 details
guidance on how to treat patients with hypertension on the
vascular ward (systolic BP >170 mmHg in the absence of
any headache, seizure or neurological deﬁcit), stratiﬁed for
whether the patient was already taking antihypertensive
medications or not. More importantly (and unlike before
2008), no CEA patient was to be discharged until his/her
blood pressure was controlled, even if this meant prolon-
gation of in-patient stay. The relevance of this is that prior
to 2008, an indeterminate proportion of patients were
probably discharged with poorly controlled blood pressureand this may explain why 36% of the ICH/HS events that did
happen occurred after discharge from hospital.31
Since January 2008, CEA patients now enter theatre re-
covery with a copy of the hypertension guidelines in their
case notes. This ensures that they are immediately available
should the need for treatment arise (irrespective of whether
this is in theatre recovery or back on the ward) and means
that less experienced staff can start appropriate medications
as soon as possible. This policy immediately led to a more
consistent and rapid implementation of treatment for post-
CEA hypertension and has been associated with virtual
abolition of ICH and HS (Table 1). Prior to implementation of
the guidelines, the prevalence of ICH/HS was 15/1701
(0.9%). Since January 2008, ICH/HS has only complicated 1/
599 CEAs (0.2%). However, the hypertension policy may also
have conferred other (serendipitous) beneﬁts.
Prevention of peri-operative cardiac events
Between 1992 and 2004, 10/1278 patients (0.8%) either
died (n ¼ 7) or suffered a stroke (n ¼ 3) following an acute
cardiac event. Seven deaths followed myocardial infarction
(n ¼ 2), acute cardiac failure (n ¼ 2) or cardiac arrest
(n ¼ 3). Two of the three strokes were haemodynamic and
secondary to severe hypotension post-cardiac arrest (n ¼ 1)
or following acute cardiac failure (n ¼ 1). The third stroke
was cardio-embolic (post-MI). Although an overall preva-
lence of 0.8% represents a relatively small proportion of
patients, by 2004, cardiac events constituted a relatively
high proportion of deaths/strokes following CEA, having
virtually abolished intra-operative stroke and stroke as a
result of POCT.
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expected) phenomenon occurred following introduction of
the dual-antiplatelet protocol in 2006 and the hyperten-
sion guidelines in 2008. Since that time, when no other
changes in selection criteria other than the introduction of
expedited CEA in 2008 have happened, no patient has died
or suffered a stroke following an acute cardiac event (0/
799).DISCUSSION
When the research programme was started in 1992, the 30-
day risk of death/stroke in Leicester was about 6%. This was
virtually identical to that observed in ECST and NASCET,1,32
where participating surgeons/centres (including Leicester)
were selected to randomise patients based on their track
record. However, it was widely accepted that were it
possible to reduce the procedural risk, the beneﬁt accruing
to the patient would increase signiﬁcantly.
Most strategies for preventing stroke after CEA fail
because they do not seek answers to appropriate ques-
tions. For example, performing CEA under locoregional
anaesthesia (LRA) is (without doubt) the best method for
determining who needs a shunt during carotid clamping.
Accordingly, it will be extremely effective in preventing
stroke as a result of haemodynamic failure. However, one
cannot also expect LRA to prevent strokes secondary to
embolisation of intraluminal thrombus following clamp
release, ICH following post-operative surges in blood
pressure or stroke following POCT. As haemodynamic
strokes constitute a relative minority of all peri-operative
strokes,33 it is perhaps not surprising that the GALA trial
failed to demonstrate that CEA under LRA conferred sig-
niﬁcant reductions in the overall 30-day rate of death/
stroke.34
Similarly; studies concluding that intra-operative
completion imaging rarely reduces the procedural risk are
similarly ﬂawed,35 as they only ever look at one aspect of
peri-operative stroke prevention. For example, no-one
would seriously expect completion angioscopy (or any
other QC method) to prevent strokes as a result of ICH, HS
or POCT, but QC methods can prevent strokes that are
secondary to technical error (e.g. retained luminal
thrombus prior to ﬂow restoration [Fig. 2]). If nothing else,
this 21-year audit has reinforced the multifactorial nature of
stroke after CEA and emphasised that for any prevention
programme to succeed, it has to address a spectrum of
potential aetiologies and cannot be limited to one single
preventive strategy.
It would, however, be disingenuous to imply that the
timeline and outcome of this project had been anticipated
from the outset. Riles had previously postulated that most
peri-operative strokes followed inadvertent technical er-
ror,36 and this was the hypothesis that was tested in the
pilot study.10 In truth; we naïvely expected to ﬁnd that
preventing technical error would prevent intra-operative
stroke (which it did), but that it would also prevent
stroke as a result of POCT (which it did not). After all,conventional teaching had always advised that most post-
operative thrombotic strokes followed uncorrected tech-
nical error.
As is evident from Table 1, our intra-operative QC and
monitoring programme had no effect on stroke as a result of
POCT.This prompted a decade of research that examined the
pathophysiology of POCT and especially the hypothesis that it
might be ‘patient mediated’. The main ﬁndings from this
period were (i) no-one undergoing re-exploration for POCT
following introduction of the intra-operative QC programme
was found to have an underlying technical error at re-
exploration,10 but that each had platelet-rich thrombus
adherent to an otherwise normal endarterectomy zone; (ii)
stroke as a result of POCTwas preceded by increasing rates of
embolisation which could be detected by TCD and about 50%
of patients with high-rate embolisation would go on to suffer
a thrombotic stroke;22,23,25e29 (iii) the ability to identify high-
risk patients with TCD before they suffered their stroke led to
innovative therapeutic strategies to abort progression on to
thrombosis using agents such as dextran-40, s-nitro-
soglutathione, tiroﬁban and abciximab;37e39 (iv) patients
undergoing staged, bilateral CEA had similar rates of embo-
lisation after each procedure despite peri-operative aspirin
therapy, suggesting an underlying patient-mediated phe-
nomenon;40 and (v) in a randomised trial, the magnitude of
post-operative embolisation was unrelated to patch type
(vein or prosthetic).41
In 1987, Stratton observed that platelet deposition within
the endarterectomy zone began within minutes of ﬂow
restoration.42 Recognition that the platelets of patients with
higher rate embolisation after CEA were more sensitive to
ADP was integral to developing novel antiplatelet strategies
for preventing POCT.30 Our policy of administering intrave-
nous dextran to a small cohort of patients with high-grade
embolisation after CEA certainly worked, but it was not
readily transferable to practices elsewhere. In reality, TCD
continues to have limited appeal,20 but (as a technique) it
was crucial in proving that dual antiplatelet therapy with
clopidogrel and aspirin could signiﬁcantly reduce post-
operative embolisation.3 A single 75-mg dose of clopidog-
rel reduced ﬁbrinogen binding to platelets in response to
ADP by about 40%,3 but was this enough to prevent stroke
as a result of POCT when interventional colleagues were
using much higher loading doses during carotid artery
stenting? In practice, it was important to achieve a balance
between securing an appropriate level of antiplatelet ac-
tivity, without increasing the risk of bleeding into the neck
(another potentially dangerous complication after CEA).
Following the randomised trial where the magnitude of
embolisation was the surrogate endpoint, there was (at the
time) little enthusiasm for a multi-centre trial and it would
have been futile to attempt an appropriately powered
single-centre randomised trial of aspirin þ placebo versus
aspirin þ clopidogrel with stroke as a result of POCT as the
endpoint. However, the prospective audit data from Table 1
(0/799 cases of POCT after dual antiplatelet therapy was
introduced in 2006) suggests that dual antiplatelet therapy
has been highly effective in preventing POCT and that it
A.R. Naylor et al. 169would be relatively easy for other units to introduce this
policy, unlike TCD and selective dextran therapy.
The other easily transferable strategy to emerge from the
21-year programme was the importance of having guide-
lines for managing post-CEA hypertension (Tables 2 and 3).
These immediately introduced a focussed and standardised
approach to management and were associated with virtual
abolition of ICH/HS. The only patient to suffer an ICH
following introduction of the guidelines (2011, Table 1)
suffered severe hypertension in the immediate post-
operative period, but was treated using the guidelines
and discharged home on day 3 with normal blood pressure.
Unfortunately, she was readmitted on day 5 with recurrent
severe hypertension, seizures and progression on to ICH.
This is the only case of recurrent severe hypertension
leading to ICH following discharge that has been encoun-
tered in the last ﬁve years (1/599 CEAs; 0.2%).
In conclusion, notwithstanding the accepted limitation
that there were no control groups (other than historical),
three strategies emerged from the 21-year programme: (i)
TCD þ angioscopy to prevent intra-operative stroke, mainly
through the detection and removal of retained luminal
thrombus prior to ﬂow restoration; (ii) dual antiplatelet
therapy to prevent stroke as a result of POCT and also
perhaps peri-operative cardiac events; and (iii) guidelines
for treating post-CEA hypertension which reduced the
prevalence of ICH/HS and which may also have reduced
major cardiac complications.
The latter two strategies are probably the easiest to
assimilate into practice elsewhere, whereas the former
requires a bit of effort. However, awareness that even the
most experienced carotid surgeon can leave intraluminal
thrombus prior to ﬂow restoration (despite careful irriga-
tion) should be a lesson to everyone. This is especially
important in the era of expedited CEA, where there are
concerns that procedural risks will increase when surgery
is performed in the hyperacute period after onset of
symptoms. Since January 2008, when all three preventive
strategies have been available to us, the 30-day rate of
death/stroke has declined to 1% (6/599). This is despite
the majority of our caseload being patients who undergo
CEA in the hyperacute period after onset of symptoms. A
signiﬁcant contributor to this low complication rate can be
attributed to obsessive attention to surgical technique, but
we also believe that the three preventive strategies
detailed in this overview have contributed signiﬁcantly
towards the sustained decline in procedural risk since
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